Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer

The surrogacy of PFS for OS in pancreatic cancer was validated. Therefore, the use of PFS as the primary end-point in clinical trials could facilitate the early introduction of new effective chemotherapy regimens into clinical practice.